Drugs

Print ISSN
0012-6667
Electronic ISSN
1179-1950
Impact factor
3.738
Publisher
Proquest
Usage rank
509
Article count
6039
Free count
0
Free percentage
0.0
PDFs via platforms
CSA, Rcgp, Proquest, Ingenta, Gale, and Ovid from 2000

  1. Pitolisant: First Global Approval.

    Drugs 76(13):1313 (2016) PMID 27438291

    Pitolisant (Wakix™) is an inverse agonist of the histamine H3 receptor that is being developed by Bioproject. Oral pitolisant is approved in the EU for the treatment of narcolepsy with or without cataplexy in adults. Pitolisant has received a Temporary Authorization of Use in France for this ind...
  2. Alitretinoin: A Review in Severe Chronic Hand Eczema.

    Drugs 76(13):1271 (2016) PMID 27438290

    Chronic hand eczema is a common but frequently disabling skin condition which poses a significant social and economic burden. Although skin protection measures and topical therapies are fundamental in its management, some patients are refractory to first-line therapy with topical corticosteroids...
  3. Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease.

    Drugs 76(13):1257 (2016) PMID 27506851

    Chronic obstructive pulmonary disease (COPD) is a disorder characterized by a complex chronic inflammatory response that is largely poorly responsive to treatment with corticosteroids. Consequently, there is a huge need to find effective anti-inflammatory agents for the treatment of patients wit...
  4. Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.

    Drugs 76(13):1245 (2016) PMID 27484675

    Vosaroxin is a first-in-class anticancer quinolone derivative that targets topoisomerase II and induces site-selective double-strand breaks in DNA, leading to tumor cell apoptosis. Vosaroxin has chemical and pharmacologic characteristics distinct from other topoisomerase II inhibitors due to its...
  5. Efmoroctocog Alfa: A Review in Haemophilia A.

    Drugs 76(13):1281 (2016) PMID 27487799

    Efmoroctocog alfa (Elocta(®), Eloctate(®), Eloctate™), a first-in-class recombinant factor VIII-Fc fusion protein (rFVIIIFc), has an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII) products. It is approved for the treatment and...
  6. Opicapone: A Review in Parkinson's Disease.

    Drugs 76(13):1293 (2016) PMID 27498199

    Oral opicapone (Ongentys(®)), a potent, third-generation, long-acting, peripheral catechol-O-methyltransferase (COMT) inhibitor, is approved as adjunctive treatment to levodopa (L-Dopa)/dopa-decarboxylase inhibitor (DDCI) therapy in adults with Parkinson's disease (PD) and end-of-dose motor fluc...
  7. Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.

    Drugs 76(13):1235 (2016) PMID 27473537

    Pasireotide (Signifor(®)) long-acting release (LAR) is a next-generation somatostatin receptor ligand (SRL) approved for treatment of patients with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option. Pasireotide LAR has been shown to be more effective ...
  8. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.

    Drugs 76(13):1301 (2016) PMID 27506852

    Tetravalent, live-attenuated, dengue vaccine (Dengvaxia(®); CYD-TDV) is the first vaccine approved for the prevention of dengue disease caused by dengue virus (DENV) serotypes 1-4 in individuals aged 9-45 or 9-60 years living in high dengue endemic areas. This narrative review discusses the immu...
  9. Diclofenac Sodium Bolus Injection (Dyloject(TM)): A Review in Acute Pain Management.

    Drugs 76(12):1213 (2016) PMID 27447189

    An intravenous bolus formulation of the non-steroidal anti-inflammatory drug diclofenac sodium has been developed using hydroxypropyl-β-cyclodextrin (HPβCD) as a solubility enhancer. HPβCD diclofenac (Dyloject(TM)) is available for use in adults in the USA for the management of mild to moderate ...
  10. Obeticholic Acid: First Global Approval.

    Drugs 76(12):1221 (2016) PMID 27406083

    Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination w...
  11. Atezolizumab: First Global Approval.

    Drugs 76(12):1227 (2016) PMID 27412122

    Atezolizumab (Tecentriq™)-a monoclonal antibody targeting programmed death ligand 1 (PD-L1 or CD274 antigen)-is being developed by Genentech as treatment for a variety of haematological malignancies and solid tumours. It been approved in the US as a second-line therapy for urothelial carcinoma a...
  12. Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.

    Drugs 76(12):1161 (2016) PMID 27412121

    Infections, including sepsis, are associated with high mortality rates in critically ill patients in the intensive care unit (ICU). Appropriate antibiotic selection and adequate dosing are important for improving patient outcomes. Daptomycin is bactericidal in bloodstream infections caused by St...
  13. Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.

    Drugs 76(12):1191 (2016) PMID 27394157

    Lumacaftor/ivacaftor (Orkambi™) is a fixed-dose tablet containing a corrector (lumacaftor) and potentiator (ivacaftor) of the cystic fibrosis transmembrane conductance regulator (CFTR) and is the first therapy approved to treat the underlying cause of cystic fibrosis in patients (aged ≥12 years)...
  14. Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.

    Drugs 76(12):1203 (2016) PMID 27401997

    A fixed-dose tablet comprising the NS5A inhibitor ombitasvir, the NS3/4A inhibitor paritaprevir and ritonavir (ombitasvir/paritaprevir/ritonavir) (Technivie(®), Viekirax(®)) is available for use, in combination with ribavirin, for the treatment of chronic hepatitis C virus (HCV) genotype 4 infec...
  15. Unmet Needs in LDL-C Lowering: When Statins Won't Do!

    Drugs 76(12):1175 (2016) PMID 27456066 PMCID PMC4974266

    The use of low-density lipoprotein cholesterol (LDL-C)-lowering medications has led to a significant reduction of cardiovascular risk in both primary and secondary prevention. Statin therapy, one of the cornerstones for the prevention and treatment of cardiovascular disease (CVD), has been demon...
  16. Sugammadex: A Review of Neuromuscular Blockade Reversal.

    Drugs 76(10):1041 (2016) PMID 27324403

    Sugammadex (Bridion(®)) is a modified γ-cyclodextrin that reverses the effect of the steroidal nondepolarizing neuromuscular blocking agents rocuronium and vecuronium. Intravenous sugammadex resulted in rapid, predictable recovery from moderate and deep neuromuscular blockade in patients undergo...
  17. Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy.

    Drugs 76(11):1119 (2016) PMID 27364753

    Myopic choroidal neovascularization (mCNV) is the second most common form of CNV after age-related macular degeneration (AMD). It is a sight-threatening complication of pathologic myopia (PM) and often affects patients in their working years causing significant impact on quality of life. Previou...
  18. Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions.

    Drugs 76(10):999 (2016) PMID 27289376 PMCID PMC4944650

    Asthma is a complex disease where many patients remain symptomatic despite guideline-directed therapy. This suggests an unmet need for alternative treatment approaches. Understanding the physiological role of muscarinic receptors and the parasympathetic nervous system in the respiratory tract wi...
  19. Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

    Drugs 76(11):1093 (2016) PMID 27312429

    Psychotic symptoms are common in Parkinson's disease (PD) and are associated with poorer quality of life and increased caregiver burden. PD psychosis is correlated with several factors, such as more advanced disease, cognitive impairment, depression, and sleep disorders. The underlying causes of...
  20. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.

    Drugs 76(11):1067 (2016) PMID 27318702

    Sphingosine-1-phosphate (S1P) and S1P receptors (S1PR) are ubiquitously expressed. S1P-S1PR signaling has been well characterized in immune trafficking and activation in innate and adaptive immune systems. However, the full extent of its involvement in the pathogenesis of autoimmune diseases is ...